Cary P. Gross, MD

Articles by Cary P. Gross, MD

Cancer Therapeutic Clinical Trials Supporting FDA Approval and Compendia Inclusion

ByKevin W. Su, MD,Cary P. Gross, MD,Nicholas S. Downing, MD,Kerin B. Adelson, MD,Joseph S. Ross, MD, MHS

July 28th 2017

Evidentiary standards for new or supplementary cancer therapeutic indication approvals by the FDA are consistent with off-label indication inclusions on Medicare-referenced compendia.

Economic Burden of Oral Tyrosine Kinase Inhibitors Among Privately Insured Patients Diagnosed With Metastatic Renal Cell Carcinoma

BySimon P. Kim, MD, MPH,Cary P. Gross, MD,Quoc-Dien Trinh, MD,Marc C. Smaldone, MD, MSHP,R. Houston Thompson, MD,Sarah P. Psutka, MD,Holly Van Houten, BA,Leona C. Han, BA,Robert Abouassaly, MD

February 11th 2016

Study investigate the economic burden from the total costs, private insurance reimbursement, and out-of-pocket costs for oral TKI agents among metastatic RCC patients.

Cary P. Gross, MD

Articles by Cary P. Gross, MD

Cancer Therapeutic Clinical Trials Supporting FDA Approval and Compendia Inclusion

Economic Burden of Oral Tyrosine Kinase Inhibitors Among Privately Insured Patients Diagnosed With Metastatic Renal Cell Carcinoma

Latest Updated Articles

Trending on Pharmacy Times

Early Recognition and Routine Discussion: Improving Outcomes in Tardive Dyskinesia

White Bagging, Brown Bagging, and the Pharmacist Caught in the Middle

Do GLP-1 Receptor Agonists Increase the Risk of Smell and Taste Disturbances?

Melatonin May Reduce Musculoskeletal Pain and Improve Sleep

Phase 3 AURORA Trial Launches to Evaluate Viral Immunotherapy in Advanced NSCLC